Growth hormone secretagogues: history, mechanism of action and clinical development

Junichi Ishida, Masakazu Saitoh, Nicole Ebner, Jochen Springer, Stefan D Anker, Stephan von Haehling

Abstract


Growth hormone secretagogues (GHSs) are a generic term to describe compounds which increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS-R), whose natural ligand is ghrelin, and agonists of the growth hormone-releasing hormone receptor (GHRH-R), to which the growth hormone-releasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosisg of GH deficiency, which causes growth retardation, gastrointestinal dysfunction and altered body composition, in parallel with extensive research to identify GHRH, GHS-R and ghrelin. This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials. Furthermore, we will highlight the publicly disclosed clinical trials regarding GHSs. 


Full Text:

PDF

References


Bowers C, Chang J, Momany F, Folkers K: Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. Molecular Endocrinology 1977:287-292.

Bowers C, Momany F, Reynolds G: In vitro and in vivo activity of a small synthetic peptide with potent GH releasing activity. In 64th Annual Meeting of the Endocrine Society, San Francisco: 1982:205.

Bowers C: GH releasing peptides-structure and kinetics. Journal of Pediatric Endocrinology and Metabolism 1993, 6:21-32.

Howard AD, Feighner SD, Cully DF, Arena JP: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273:974.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.

Prakash A, Goa KL: Sermorelin. BioDrugs 1999, 12:139-157.

Barron JL, Coy DH, Millar RP: Growth hormone responses to growth hormone-releasing hormine (1–29)-NH 2 and a D-Ala 2 analog in normal men. Peptides 1985, 6:575-577.

Carpino PA: Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists. Expert Opinion on Therapeutic Patents 2002, 12:1599-1618.

Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E: Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997, 18:885-891.

Imbimbo B, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R: Growth hormone-releasing activity of hexarelin in humans. European journal of clinical pharmacology 1994, 46:421-425.

Rahim A, O’Neill PA, Shalet SM: Growth hormone status during long-term hexarelin therapy. The Journal of Clinical Endocrinology & Metabolism 1998, 83:1644-1649.

Broglio F, Benso A, Gottero C, Muccioli G, Deghenghi R, Ghigo E, Arvat E: Endocrine activities of alexamorelin (Ala-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), a synthetic GH secretagogue, in humans. European journal of endocrinology 2000, 143:419-425.

Suckling K: Discontinued drugs in 2005: cardiovascular drugs. Expert opinion on investigational drugs 2006, 15:1299-1308.

Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M: Pharmacological characterisation of a new oral GH secretagogue, NN703. European journal of endocrinology 1999, 141:180-189.

Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, Falch JE, Ilondo MM: The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Hormone & IGF Research 2000, 10:193-198.

Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, Søgaard B, Ynddal L, Ilondo MM: The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. Growth Hormone & IGF Research 2001, 11:41-48.

Svensson J, Monson J, Vetter T, Hansen T, Savine R, Kann P, Bex M, Reincke M, Hagen C, Beckers A: Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clinical endocrinology 2003, 58:572-580.

Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM: A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. European journal of clinical pharmacology 2003, 58:683-688.

Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumic M: General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung 2004, 54:868-880.

Editorial A: Pralmorelin: GHRP 2, GPA 748, Growth Hormone-Releasing Peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R & D 2004, 5:236-239.

Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghe C, Catapano F, Torsello A, Locatelli V: EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. Journal of endocrinological investigation 2002, 25:RC26-RC28.

Piccoli F, Degen L, MacLean C, Peter S, Baselgia L, Larsen F, Beglinger C, Drewe Jr: Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. The Journal of Clinical Endocrinology & Metabolism 2007, 92:1814-1820.

Pustovit R, Callaghan B, Kosari S, Rivera L, Thomas H, Brock J, Furness J: The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. Neurogastroenterology & Motility 2014, 26:264-271.

Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH: Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology 1998, 139:552-561.

Gobburu JV, Agersø H, Jusko WJ, Ynddal L: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research 1999, 16:1412-1416.

Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B: Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics 2009, 329:1110-1116.

Wargin W, Thomas H, Clohs L, St-Louis C, Ejskjaer N, Gutierrez M, Shaughnessy L, Kosutic G: Contribution of Protein Binding to the Pharmacokinetics of the Ghrelin Receptor Agonist TZP-101 in Healthy Volunteers and Adults with Symptomatic Gastroparesis. Clinical drug investigation 2009, 29:409-418.

Lasseter KC, Shaughnessy L, Cummings D, Pezzullo JC, Wargin W, Gagnon R, Oliva J, Kosutic G: Ghrelin Agonist (TZP‐101): Safety, Pharmacokinetics and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First‐in‐Human Study. The Journal of Clinical Pharmacology 2008, 48:193-202.

Fraser G, Hoveyda H, Venkova K, Johnson A, Samia M, Greenwood-Van Meerveld B, Tannenbaum G: Pharmacological separation of the gastrointestinal and endocrine effects of ghrelin using a novel ghrelin agonist, Tzp-101. Neurogastroenterology & Motility 2005, 17:85.

Venkova K, Fraser G, Hoveyda H, Greenwood-van Meerveld B: Ghrelin agonist activity in a rat model of postoperative hens and opioid-delayed gastrointestinal motility. In Gastroenterology: WB SAUNDERS CO-ELSEVIER INC 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA: 2006:A5-A5.

Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen L, Sarosiek I, Søfteland E, Nowak T, Pezzullo J, Shaughnessy L: Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterology & Motility 2010, 22:1069.

Broad J, Callaghan B, Sanger GJ, Brock JA, Furness JB: Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. European journal of pharmacology 2015, 752:34-39.

Camilleri M, Acosta A: Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterology & Motility 2015, 27:324-332.

Van der Ploeg L, Laken H, Sharma S, Datta R, Halem H, Dong J, Touvay C, Teillot M, Noonan P, Tartaglia L: Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sciences 2014, 109:20-29.

Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, Zinsmeister AR: Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying. Diabetes Care 2013, 36:41-48.

Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D, Zinsmeister AR: The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clinical Gastroenterology and Hepatology 2013, 11:1453-1459. e1454.

Ejskjaer N, Vestergaard ET, Hellström PM, Gormsen L, Madsbad S, Madsen J, Jensen T, Pezzullo J, Christiansen J, Shaughnessy L: Ghrelin receptor agonist (TZP‐101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Alimentary pharmacology & therapeutics 2009, 29:1179-1187.

Welle S, Thornton C, Statt M, McHenry B: Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. The Journal of Clinical Endocrinology & Metabolism 1996, 81:3239-3243.

Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB: Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Hormone Research in Paediatrics 1999, 51:78-84.

Adams GR, McCue SA: Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. Journal of Applied Physiology 1998, 84:1716-1722.

Patchett A, Nargund R, Tata J, Chen M, Barakat K, Johnston D, Cheng K, Chan W, Butler B, Hickey G: Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences 1995, 92:7001-7005.

Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora Jr D, Nargund R, Patchett A: MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 1996, 137:5284-5289.

Svensson J, Lonn L, Jansson J-O, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. The Journal of Clinical Endocrinology & Metabolism 1998, 83:362-369.

Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of Clinical Endocrinology & Metabolism 1996, 81:4249-4257.

Murphy M, Plunkett L, Gertz B, He W, Wittreich J, Polvino W, Clemmons D: MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of Clinical Endocrinology & Metabolism 1998, 83:320-325.

Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA: MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of gerontology and geriatrics 2011, 53:183-189.

Dubreuil P, Désévaux C: Growth Hormone-Releasing Factor: Structural Modification or Protection for More Potent Analogs. Combinatorial chemistry & high throughput screening 2006, 9:171-174.

Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P: Non‐Clinical Pharmacology and Safety Evaluation of TH9507, a Human Growth Hormone‐Releasing Factor Analogue. Basic & clinical pharmacology & toxicology 2007, 100:49-58.

Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S: Growth hormone–releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004, 292:210-218.

Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Murray MC, Cook ER, DiBrino JN, DeNinno SL, Chidsey-Frink KL: Discovery and biological characterization of capromorelin analogues with extended half-lives. Bioorganic & medicinal chemistry letters 2002, 12:3279-3282.

Pan LC, Carpino PA, Lefker BA, Ragan JA, Toler SM, Pettersen JC, Nettleton DO, Ng O, Pirie CM, Chidsey-Frink K: Preclinical pharmacology of CP-424,391, and orally active pyrazolinone-piperidine growth hormone secretagogue. Endocrine 2001, 14:121-132.

Thompson D: Aging and sarcopenia. Journal of Musculoskeletal and Neuronal Interactions 2007, 7:344.

Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R: Anamorelin HCl (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile. Journal of Cachexia, Sarcopenia and Muscle 2014, 5:329-337.

Garcia JM, Polvino WJ: Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. The oncologist 2007, 12:594-600.

Garcia JM, Polvino WJ: Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Hormone & IGF Research 2009, 19:267-273.

Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology 2016, 17:519-531.

Currow DC, Temel JS, Fearon K, Yan Y, Friend J, Abernethy AP: A safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia: ROMANA 3. Edited by: American Society of Clinical Oncology; 2015.

Losa M, Schopohl J, Müller O, Von Werder K: Stimulation of growth hormone secretion with human growth hormone releasing factors (GRF 1–44, GRF 1–40, GRF 1–29) in normal subjects. Journal of Molecular Medicine 1984, 62:1140-1143.

Prakash A, Goa KL: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 1999, 12:139-157.

Neyzi O, Yordam N, Oca G, Bundak R, Darendeliler F, AGikǧoz E, Berberoglu M, Günoz H, Saka N, Calikoglu AS: Growth response to growth hormone releasing hormone (1–29)-NH2 compared with growth hormone. Acta Paediatrica 1993, 82:16-21.

Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S: Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. The Journal of Clinical Endocrinology & Metabolism 1996, 81:1189-1196.

Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS: Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiology of aging 2006, 27:318-323.

McIntyre J, Martin L: Pralmorelin: Diagnosis and treatment of growth hormone deficiency growth hormone secretagogue. Drugs of the future 2005, 30:124-127.

Mericq Vn, Cassorla F, Salazar T, Avila A, Iñiguez Gn, Bowers CY, Merriam GR: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. The Journal of Clinical Endocrinology & Metabolism 1998, 83:2355-2360.

Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller B, Cook D, Yuen K, Bonert V, Dobs A: Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. The Journal of Clinical Endocrinology & Metabolism 2013, 98:2422-2429.

Beck DE, Sweeney WB, McCarter MD, Group IS: Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease 2014, 29:1527-1534.

Mosińska P, Zatorski H, Storr M, Fichna J: Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. Journal of Neurogastroenterology and Motility 2017, 23:171.

Shaw M, Pediconi C, McVey D, Mondou E, Quinn J, Chamblin B, Rousseau F: Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials. Diseases of the Colon & Rectum 2013, 56:888-897.

Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ: The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial. Diseases of the Colon & Rectum 2010, 53:126-134.

Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, White J, Currie M, Gottesdiener K, Stoner E: Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology 2016, 151:87-96. e86.

Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR: Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial. Clinical Gastroenterology and Hepatology 2015, 13:2312-2319. e2311.

Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D: Short-term effects of relamorelin on descending colon motility in chronic constipation: a randomized, controlled trial. Digestive diseases and sciences 2016, 61:852-860.

Ejskjaer N, Wo J, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L, Malik R, Hellström PM, Mondou E, Quinn J: A phase 2a, randomized, double‐blind 28‐day study of TZP‐102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology & Motility 2013, 25:e140-e150.

McCallum R, Lembo A, Esfandyari T, Bhandari B, Ejskjaer N, Cosentino C, Helton N, Mondou E, Quinn J, Rousseau F: Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology & Motility 2013, 25.

Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell Jr FE, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008, 149:601-611.

Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier B, Routy J-P, Cote P, Abribat T: A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. Aids 2005, 19:1279-1287.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J: Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine 2007, 357:2359-2370.

Falutz J, Allas S, Mamputu J-C, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J: Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. Aids 2008, 22:1719-1728.

Falutz J, Potvin D, Mamputu J-C, Assaad H, Zoltowska M, Michaud S-E, Berger D, Somero M, Moyle G, Brown S: Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension. JAIDS Journal of Acquired Immune Deficiency Syndromes 2010, 53:311-322.

Sivakumar T, Mechanic O, Fehmie D, Paul B: Growth hormone axis treatments for HIV‐associated lipodystrophy: a systematic review of placebo‐controlled trials. HIV medicine 2011, 12:453-462.

White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, Wei JY, Hoffman AR, Salvatori R, Ettinger MP: Effects of an oral growth hormone secretagogue in older adults. The Journal of Clinical Endocrinology & Metabolism 2009, 94:1198-1206.

Hersch EC, Merriam GR: Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clinical interventions in aging 2008, 3:121.

Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC: ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of Oncology 2017, 28:1949-1956.

Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A: Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Supportive Care in Cancer 2016, 24:3495-3505.

Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, et al.: PubChem Substance and Compound databases. Nucleic Acids Research 2016, 44:D1202-D1213.


Refbacks

  • There are currently no refbacks.